Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Position Statement on Noninvasive Seizure Detection/Alerting Devices: A Joint Statement of the American Epilepsy Society, the Epilepsy Foundation, and the Danny Did Foundation.

Epilepsy currents·2026
Same author

Predicting seizure freedom in the postpartum period: Findings from the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs study.

Epilepsia·2026
Same author

Sleep and Cognitive Health Interventions to Prevent Cognitive Decline in Older Adult Survivors of Critical Illness: Randomized Clinical Trial Protocol.

Nursing research·2026
Same author

Patterns of seizure frequency reduction in clinical trial participants with lower baseline seizure frequency.

Epilepsia·2026
Same author

Suicidality at Epilepsy Diagnosis and Future Treatment Resistance in Adults With Focal Epilepsy.

JAMA neurology·2026
Same author

Longitudinal pain intensity and interference symptomatology in mild traumatic brain injury: a TRACK-TBI study.

Pain·2026

Related Experiment Video

Updated: May 27, 2026

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
13:18

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression

Published on: April 10, 2026

Lamotrigine XR conversion to monotherapy: first study using a historical control group.

Jacqueline A French1, Nancy R Temkin, Bassel F Shneker

  • 1NYU Comprehensive Epilepsy Center, New York, NY 10016, USA. Jacqueline.French@nyumc.org

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|December 6, 2011
PubMed
Summary

Lamotrigine extended-release (LTG XR) effectively treated partial seizures in patients 13 and older. This study used a novel historical control design, demonstrating LTG XR

Related Experiment Videos

Last Updated: May 27, 2026

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
13:18

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression

Published on: April 10, 2026

Area of Science:

  • Neurology
  • Clinical Pharmacology
  • Epilepsy Research

Background:

  • Partial epilepsy management often involves polytherapy.
  • Conversion to monotherapy is a treatment strategy for uncontrolled epilepsy.
  • Lamotrigine extended-release (LTG XR) offers a once-daily dosing option.

Purpose of the Study:

  • To evaluate the efficacy and safety of lamotrigine extended-release (LTG XR) as monotherapy for partial seizures.
  • To utilize a United States Food and Drug Administration-approved conversion-to-monotherapy design with historical controls.
  • To assess LTG XR's effectiveness in patients aged 13 and older with uncontrolled partial epilepsy.

Main Methods:

  • A conversion-to-monotherapy design was employed, using historical data as controls.
  • Patients with uncontrolled partial epilepsy were converted to once-daily LTG XR (250 mg or 300 mg).
  • Efficacy was determined by comparing seizure worsening rates against aggregated pseudoplacebo data from prior trials.

Main Results:

  • The upper 95% confidence limits for LTG XR (250 mg and 300 mg) did not overlap with the historical control's lower 95% prediction interval (65.3%).
  • LTG XR demonstrated efficacy in treating partial seizures, with specific upper confidence limits of 43.4% (250 mg) and 37.2% (300 mg).
  • Adverse events were reported in 53% (300 mg) and 61% (250 mg) of patients.

Conclusions:

  • Once-daily lamotrigine extended-release (LTG XR) at 250 mg or 300 mg is effective for converting patients with partial seizures to monotherapy.
  • The study represents the first epilepsy trial using a historical control design to complete enrollment.
  • LTG XR provides a viable monotherapy option for adolescents and adults with partial epilepsy.